Aim: To document the causal association of iron deficiency anaemia (IDA) and intracranial hypertension (IH). Methods: A consecutive case note review of patients with a clinical diagnosis of idiopathic intracranial hypertension (IIH) and anaemia presenting to a tertiary referral unit over a 2.5-year period. Demographics, aetiology and clinical details were recorded and analysed. Results: Eight cases were identified from 77 new cases presenting with IIH. All 8 had documented microcytic anaemia with clinical evidence of raised intracranial pressure. There was no evidence of venous sinus thrombosis on MRI and MR venography in 7 subjects and on repeated CT venography in 1. On correction of anaemia alone, 7 cases resolved. One patient with severe progressive visual loss underwent ventriculoperitoneal shunt in addition to treatment of anaemia, with good outcome. The incidence of this association is 10.3%. Conclusion: These cases present an association between IDA and IH, in the absence of cerebral sinus thrombosis. As a clinically significant proportion of cases presenting with signs of IIH have IDA, we recommend all patients presenting with IIH have full blood counts and if they are found to be anaemic, they should be treated appropriately.

1.
Corbett JJ, Savino PJ, Thompson HS, Kansu T, Schatz NJ, Orr LS, Hopson D: Visual loss in pseudotumor cerebri. Follow-up of 57 patients from 5 to 41 years and a profile of 14 patients with permanent severe visual loss. Arch Neurol 1982;39:461–474.
2.
Orcutt JC, Page NG, Sanders MD: Factors affecting visual loss in benign intracranial hypertension. Ophthalmology 1984;91:1303–1312.
3.
Tugal O, Jacobson R, Berezin S, Foreman S, Berezin S, Brudnicki A, Godine L, Davidian MM, Jayabose S, Escobedo V: Recurrent benign intracranial hypertension due to iron deficiency anemia. Case report and review of literature. Am J Pediatr Hematol Oncol 1994;16:266–270.
4.
Giuseffi V, Wall M, Siegel PZ, Rojas PB: Symptoms and disease associations in idiopathic intracranial hypertension (pseudotumor cerebri): a case-control study. Neurology 1991;41:239–244.
5.
Friedman DI, Jacobson DM: Diagnostic criteria for idiopathic intracranial hypertension. Neurology 2002;59:1492–1495.
6.
Ball AK, Clarke CE: Idiopathic intracranial hypertension. Lancet Neurol 2006;5:433–442.
7.
World Health Organization: Iron Deficiency Anaemia: Assessment, Prevention and Control. Geneva, World Health Organization, 2001.
8.
Biousse V, Rucker JC, Vignal C, Crassard I, Katz BJ, Newman NJ: Anemia and papilledema. Am J Ophthamol 2003;135:437–446.
9.
Ireland B, Corbett JJ, Wallace RB: The search for causes of idiopathic intracranial hypertension. A preliminary case-control study. Arch Neurol 1990;47:315–320.
10.
Rowe FJ, Sarkies NJ: The relationship between obesity and idiopathic intracranial hypertension. Int J Obes Relat Metab Disord 1999;23:54–59.
11.
Wall M, George D: Idiopathic intracranial hypertension. A prospective study of 50 patients. Brain 1991;114:155–180.
12.
Kupersmith MJ, Gamell L, Turbin R, Peck V, Spiegel P, Wall M: Effects of weight loss on the course of idiopathic intracranial hypertension in women. Neurology 1998;50:1094–1098.
13.
Weisberg LA: Benign intracranial hypertension. Medicine (Baltimore) 1975;54:197–207.
14.
Johnston I, Paterson A: Benign intracranial hypertension. 2. CSF pressure and circulation. Brain 1974;97:301–312.
15.
Sussman J, Leach M, Greaves M, Malia R, Davies-Jones GA: Potentially prothrombotic abnormalities of coagulation in benign intracranial hypertension. J Neurol Neurosurg Psychiatry 1997;62:229–233.
16.
Stolz E, Valdueza JM, Grebe M, Schlachetzki F, Schmitt E, Madlener K, Rahimi A, Kempkes-Matthes B, Blaes F, Gerriets T, Kaps M: Anemia as a risk factor for cerebral venous thrombosis? An old hypothesis revisited. Results of a prospective study. J Neurol 2007;254:729–734.
17.
Koh L, Zakharov A, Johnston M: Integration of the subarachnoid space and lymphatics: is it time to embrace a new concept of cerebrospinal fluid absorption? Cerebrospinal Fluid Res 2005;2:6.
18.
Eisenstein RS, Ros KL: Novel roles for iron regulatory proteins in the adaptive response to iron deficiency. J Nutr 2003;133:1510S–1516S.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.